Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AT-1501-K209: BESTOW-EXTENSION: A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT06126380 is registered in ClinicalTrials.gov with Eledon Pharmaceuticals as lead sponsor.

NCT NCT06126380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06126380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AT-1501-K209: BESTOW-EXTENSION: A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
Lead sponsor
Eledon Pharmaceuticals
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
October 25, 2023
Completion date
December 31, 2029
Enrollment
132 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant rejection